ABBVIE INC. (ABBV)
AbbVie Inc. (ABBV) is a global biopharmaceutical company founded in 2013 as a spin-off from Abbott Laboratories. It specializes in the research, development, and marketing of innovative medicines across a range of therapeutic areas, including immunology, oncology, virology, and neuroscience. AbbVie is known for its flagship product, Humira, a leading treatment for autoimmune diseases. The company focuses on advancing scientific discoveries to deliver novel therapies and improve patient outcomes worldwide.
Dividend History
Investors can expect a dividend payout of $1.64 per share, scheduled to be distributed in 38 days on November 14, 2025
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| November 14, 2025 | $1.64 | 2025-10-15 | 2025-10-15 |
| August 15, 2025 | $1.64 | 2025-07-15 | 2025-07-15 |
| May 15, 2025 | $1.64 | 2025-04-15 | 2025-04-15 |
| February 14, 2025 | $1.64 | 2025-01-15 | 2025-01-15 |
| November 15, 2024 | $1.55 | 2024-10-15 | 2024-10-15 |
Dividends Summary
- ABBVIE INC. has issued 52 dividend payments over the past 12 years
- The most recent dividend was paid 53 days ago, on August 15, 2025
- The highest dividend payed out to investors during this period was $1.64 per share
- The average dividend paid during this period was $1.00 per share.
Company News
AbbVie announced a $70 million expansion of its Bioresearch Center in Worcester, Massachusetts, focusing on biologics research and manufacturing. The project aligns with the Trump administration's goal of increasing domestic corporate assets and is part of AbbVie's broader $10 billion biologics advancement strategy.
Nxera Pharma announced receiving a US$10 million milestone payment from AbbVie as part of their multi-target discovery collaboration focused on neurological diseases, marking their second milestone in the partnership.
AbbVie announced a quarterly cash dividend of $1.64 per share, payable on November 14, 2025, to stockholders of record as of October 15, 2025. The company has increased its dividend by 310% since its inception in 2013 and is a member of the S&P Dividend Aristocrats Index.
The healthcare sector is experiencing low valuations and potential for a quiet rebound, with improving technical indicators and significant institutional investment despite ongoing political and economic challenges.
The article discusses the Invesco Large Cap Value ETF (PWV), which provides broad exposure to the large-cap value segment of the market. It highlights the fund's investment strategy, performance, and risk profile, as well as compares it to similar ETFs like Schwab U.S. Dividend Equity ETF (SCHD) and Vanguard Value ETF (VTV).
